Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with XELOX in Gastric Cancer with Liver Metastasis
NCT01962376Phase 4Unknown
- Sponsor
- Hebei Medical University
- Start
- Feb 2013
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bevacizumab in gastric cancer (GC) and liver metastasis (2 arms), sponsored by Hebei Medical University. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
gastric cancer (GC)liver metastasis
Beyond the preview
Go deeper on NCT01962376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01962376.